Zentalis Pharmaceuticals (ZNTL) Non-Current Deferred Tax Liability (2019 - 2023)

Zentalis Pharmaceuticals' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $756000.0 for Q1 2023.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 51.16% year-over-year to $756000.0 in Q1 2023; TTM through Mar 2023 was $756000.0, a 51.16% decrease from a year earlier, with the FY2022 full-year figure at $853000.0, down 95.54% from the prior year.
• Non-Current Deferred Tax Liability declined to $756000.0 in Q1 2023 per ZNTL's latest filing, from $853000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $19.1 million in Q4 2021 and bottomed at $756000.0 in Q1 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $2.5 million (2019), against an average of $3.1 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 671.77% in 2021 and plunged 95.54% in 2022, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $2.5 million in 2019, then climbed by 0.69% to $2.5 million in 2020, then jumped by 671.77% to $19.1 million in 2021, then plunged by 95.54% to $853000.0 in 2022, then retreated by 11.37% to $756000.0 in 2023.
• Per Business Quant, the three latest ZNTL Non-Current Deferred Tax Liability figures stand at $756000.0 (Q1 2023), $853000.0 (Q4 2022), and $1.2 million (Q3 2022).